Intravenous-to-Subcutaneous Drug Markets

  • ID: 3802075
  • Report
  • Region: Global
  • Greystone Associates
1 of 3
By Pursuing Intravenous-To-Subcutaneous Drug Markets, Drug Owners are Finding they can Achieve a Number of Competitive Advantages
The number of drugs based on biologicals continues to grow at an increasingly rapid rate. Because of their physical properties and the relatively high administration volumes often required to achieve the desired therapeutic effect, the majority are developed and launched for intravenous administration. This is creating a burgeoning demand for infusion facilities, personnel and equipment.

The relative complexity, costs and patient logistics associated with IV infusion relative to other routes of administration is creating interest in post-launch re-engineering of IV drugs to allow them to be administered subcutaneously. A number of technology approaches are currently being employed to accomplish this migration. By pursuing intravenous-to-subcutaneous drug markets, drug owners are finding they can achieve a number of competitive advantages.

What You Will Learn

- What intravenous drugs have been strategically re-engineered for subcutaneous administration, what are the technologies being used, and what is their current market status?

- What are the therapeutic markets that are viewed as having the greatest potential for IV-to-SC migration?

- What are the major factors driving intravenous-to-subcutaneous drug re-engineering?

- How are intravenous-to-subcutaneous drugs currently aligned with drug classes and therapeutic markets?

- What intravenous drugs are currently being developed for eventual release as subcutaneously administered drugs, and what is their current status?

- What is the market impact of IV-to-SC drug migration? What will it be in 2020?

- Who are the significant players in this segment? What are their strategies? Who are their alliance partners?
Note: Product cover images may vary from those shown
2 of 3
1. Executive Summary

2. The Market Opportunity

3. Market Sector Dynamics
- IV-to-SC Administration -The Opportunity
- Intravenous-to-Subcutaneous Market Drivers
- Managed Care and Healthcare Economics
- Patient Sentiment
- Delivery Device Innovation
- Patent/Life Cycle Strategies
- Competitive Landscape
- Risk Factors

4. Intravenous-to-Subcutaneous Technology
- Drug Formulation
- Injection Site Modification
- Delivery Device Innovation
- Development Factors
- Human Engineering/Ergonomics
- Lyophilized Drugs/Reconstitution

5. IV-to-SC - Drug Product Analysis
- Antibiotics
- Antibodies
- Anticoagulants
- Antiemetics
- Blood Factors
- Diuretics
- Hormones
- Plasma-derived Immune Inhibitors
- Recombinant Immunotherapeutics
- Vasodilators

6. IV-to-SC - Therapeutic Sector Analysis
- Cardiology
- Edema
- Hypertension
- Platelet Inhibition
- Hematology
- Multiple Sclerosis
- Oncology
- Reproductive Health

7. Market Factors

8. Regulatory Issues
- Collaborations and Alliances
- Emerging Technologies

9. Company Profiles
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown